13.1 Nephrolithiasis, BPH, Prostate Cancer & Increased Intracranial Pressure

Urology: Nephrolithiasis

Nephrolithiasis, or kidney stones, is a highly prevalent condition characterized by the formation of crystalline stones within the urinary tract. The most common type is calcium oxalate, followed by calcium phosphate, uric acid, struvite (associated with urease-producing organisms like Proteus), and cystine. Patients classically present with sudden-onset, severe, colicky flank pain that may radiate to the groin, accompanied by nausea, vomiting, and hematuria. Non-contrast CT of the abdomen and pelvis is the gold standard diagnostic test, offering high sensitivity and specificity. Management depends on stone size and location. Small stones (< 5 mm) typically pass spontaneously and can be managed conservatively with hydration, analgesia (NSAIDs are preferred), and alpha-blockers like tamsulosin to facilitate passage. Stones between 5 mm and 10 mm have a variable passage rate and may require intervention. For stones > 10 mm or those causing intractable pain, significant obstruction, or infection, urological intervention such as shock wave lithotripsy (SWL), ureteroscopy (URS), or percutaneous nephrolithotomy (PCNL) is necessary.

Urology: Benign Prostatic Hyperplasia (BPH)

BPH is a non-malignant enlargement of the prostate gland, common in older men, leading to lower urinary tract symptoms (LUTS). These symptoms are categorized into storage (frequency, urgency, nocturia) and voiding (hesitancy, weak stream, intermittency, incomplete emptying). Initial evaluation includes a thorough history, validated symptom score (e.g., IPSS), digital rectal exam (DRE) revealing a smoothly enlarged prostate, urinalysis to rule out infection, and serum PSA. Medical management is the first-line treatment for moderate to severe symptoms. Alpha-1 adrenergic antagonists (e.g., tamsulosin, alfuzosin) provide rapid symptom relief by relaxing prostatic smooth muscle. 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) reduce prostate volume over several months by blocking the conversion of testosterone to dihydrotestosterone and are typically reserved for patients with significantly enlarged prostates. Combination therapy is highly effective for severe symptoms and large prostates. Surgical intervention, most commonly Transurethral Resection of the Prostate (TURP), is indicated for refractory cases, recurrent urinary retention, recurrent UTIs, bladder stones, or renal impairment due to BPH.

Urology: Prostate Cancer

Prostate cancer is one of the most common malignancies in men. It is often asymptomatic in early stages, detected through an elevated Prostate-Specific Antigen (PSA) level or an abnormal DRE (nodular, hard, asymmetrical prostate). When symptomatic, it may present similarly to BPH or with bone pain from metastases (commonly to the axial skeleton). Diagnosis is confirmed via Transrectal Ultrasound (TRUS)-guided prostate biopsy. The Gleason grading system is critical for determining the aggressiveness of the tumor. Treatment strategies vary widely based on the patient's life expectancy, tumor stage, and Gleason score. Active surveillance is a recognized approach for low-risk disease. Localized prostate cancer may be treated with radical prostatectomy or radiation therapy (external beam or brachytherapy). Advanced or metastatic disease is primarily managed with androgen deprivation therapy (ADT), utilizing GnRH agonists (with concurrent antiandrogens initially to prevent testosterone flare) or antagonists.

Neurosurgery: Increased Intracranial Pressure (ICP)

Increased ICP is a life-threatening neurological emergency that can result from various etiologies, including traumatic brain injury (TBI), intracranial hemorrhage, brain tumors, hydrocephalus, or cerebral edema. The Monro-Kellie doctrine states that the cranial vault has a fixed volume containing brain tissue, blood, and cerebrospinal fluid (CSF); an increase in one component must be compensated by a decrease in others, lest ICP rise precipitously. Early signs of elevated ICP include headache, nausea, vomiting (often projectile), and altered mental status. As ICP continues to rise, patients may exhibit focal neurological deficits, papilledema, and eventually Cushing's triad (hypertension, bradycardia, and irregular respirations), which indicates impending brain herniation. Management focuses on rapidly reducing ICP while maintaining adequate cerebral perfusion pressure (CPP). Immediate interventions include elevating the head of the bed to 30 degrees, optimizing venous drainage, hyperventilation (to induce vasoconstriction and reduce cerebral blood volume, though used cautiously), and osmotic therapy with mannitol or hypertonic saline. Sedation and analgesia are crucial to minimize metabolic demand. Definitive treatment requires addressing the underlying cause, which may involve surgical decompression (e.g., craniectomy, hematoma evacuation) or CSF diversion (e.g., external ventricular drain).

Neurosurgery: Glasgow Coma Scale (GCS)

The Glasgow Coma Scale is a standardized, objective tool used to assess a patient's level of consciousness, particularly following a traumatic brain injury. It evaluates three parameters: Eye Opening (scored 1-4), Verbal Response (scored 1-5), and Motor Response (scored 1-6). The total score ranges from 3 to 15.

Eye Opening (E):

• 4: Spontaneous
• 3: To speech
• 2: To pain
• 1: None

Verbal Response (V):

• 5: Oriented
• 4: Confused
• 3: Inappropriate words
• 2: Incomprehensible sounds
• 1: None

Motor Response (M):

• 6: Obeys commands
• 5: Localizes to pain
• 4: Withdraws from pain
• 3: Abnormal flexion (decorticate posturing)
• 2: Abnormal extension (decerebrate posturing)
• 1: None

A GCS score of 13-15 indicates mild head injury, 9-12 indicates moderate injury, and 8 or less signifies severe head injury. The classic teaching 'GCS of 8, intubate' underscores the critical need for definitive airway management in these severely compromised patients to prevent aspiration and ensure adequate oxygenation and ventilation.